REG - IXICO plc - Contract award worth circa £1.0m

IXICOAnnouncement

08/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220208:nRSH9433Aa&default-theme=true

RNS Number : 9433A  IXICO plc  08 February 2022

IXICO plc

("IXICO" or the "Company")

 

Contract award worth circa £1.0m for Phase 1b/2 trial in neurodegenerative
diseases

 

IXICO plc (AIM: IXI), the  medical imaging advanced analytics company
delivering intelligent insights in neuroscience is pleased to announce that it
has been selected to provide PET and MRI imaging services to a leading
European biopharmaceutical company specialising in neurodegenerative
conditions.  The trial is a Phase 1b/2 clinical trial and relates to the use
of a novel compound to target amyloid in neurodegenerative diseases.

 

The sponsor is a new client for IXICO, and this trial will run over
approximately five years. This study will include participants with
Alzheimer's disease ('AD') as well as participants with Down Syndrome. AD
continues to be the number one indication in clinical research with a
continued focus on the amyloid target. This study confirms IXICO's leading
role supporting sponsors dedicated to finding treatments for this disease.

 

IXICO is providing end to end support to the sponsor for this trial: from
consultation in planning and design of the imaging protocols to the set up and
management of imaging centres, collection and control of imaging data
(including Amyloid and Tau PET), radiology and subsequent analysis and
reporting of data.

 

Having built an extensive portfolio of proprietary imaging data management and
analysis technologies for investigation of neurological disorders, IXICO is
able to provide advanced neuroimaging solutions and services from Phase I
through to commercialisation. In this trial, IXICO will deploy a range of
advanced MRI modalities, including volumetric, diffusion (DTI), perfusion
(ASL) and functional (BOLD) MRI. IXICO will provide radiology and quantitative
analysis services to support patient selection, safety, and efficacy analysis.

 

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this
contract. Our success in being awarded this study with another new client
follows on from our success in securing contracts with nine new clients during
the last financial year and is a further contract that utilises both our MRI
and PET service portfolios. Our mission is to support our clients in their
tireless efforts to bring potential treatments to patients suffering from
neurological disorders, and this contract reflects the confidence that
increasing numbers of companies are placing in IXICO as their trusted
neuroimaging partner for their important CNS studies."

 

For further information please contact:

 

 IXICO plc                                                                +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                                 +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

 Walbrook PR Ltd            IXICO@walbrookpr.com
 Paul McManus / Lianne Applegarth /Alice Woodings      +44 (0)20 7933 8780

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBKOBBOBKDNBK